This email wraps up 2016. Thanks for being a subscriber! Over 350,000 IPPractice emails were sent over the year to over 1500 subscribers, listing 450 new intellectual property proceedings and reporting 180 decisions. I’m looking forward to more developments in 2017. Happy New Year!

Some more stats from the past year are on the website.

New proceedings: 396 from the Federal Court, 57 from the Federal Court of Appeal which includes actions, applications and pre-leave proceedings (added for the first time late last year).

New Decisions: 132 from the Federal Courts and 51 from other courts.

Supreme Court: reported on 10 Supreme Court of Canada proceedings, six of which are still pending (under reserve or pending leave applications).

Copyright Board: over 120 rulings, decisions and updates report.

Trademark Opposition Board: over 200 decisions reported

Health Canada: over 800 newly listed patents on the Patent Register identified and 43 new innovative drugs

Domain names: 24 new CIRA domain name decisions

Patent Appeal Board: 24 new PAB decisions

I posted about 45 blog posts, of these along with my case summaries, among the most popular were:

  1. Patent Agent list
  2. Trademark Agent list
  3. Announcement of my move to DLA Piper
  4. Report on the intervenors in the AstraZeneca ‘promise doctrine’ appeal at the Supreme Court
  5. Listing of the top Canadian patentees
  6. Report on the NAFTA arbitration brought by Eli Lilly
  7. Report on Sim & McBurney v Aird & McBurney LP
  8. Report the Federal Court of Appeal’s five-member decision on standard of review in Hospira Healthcare Corporation v The Kennedy Institute of Rheumatology
  9. Report on Pollard Banknote Limited v. BABN Technologies Corp
  10. Report on CETA implementation and the overhaul of the PM(NOC) Regulations

As for 2017, there is potentially lots happening for intellectual property in Canada including the release of two major decisions on the ‘promise doctrine’ (the Supreme Court of Canada in AstraZeneca and in Eli Lilly’s NAFTA arbitration), an overhaul of the PM(NOC) Regulations, and perhaps some implementation details for the Patent Law Treaty and the Madrid Treaty.